EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration

Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo iD, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino iD, Ernesto Vigna und 2 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70458 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Santino Caserta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic, Protein Kinase Inhibitors, Receptor Protein-Tyrosine Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mature T‐cell lymphomas comprise a heterogeneous group of aggressive non‐Hodgkin lymphomas with limited therapeutic options in the relapsed or refractory setting. Among them, anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALCL) represents a biologically distinct subtype driven by constitutive activation of ALK fusion proteins, which promote oncogenic signalling through signal transducer and activator of transcription 3, phosphatidylinositol 3‐kinase (PI3K)/AKT Serine/Threonine Kinase 1 (AKT)/mammalian target of rapamycin (mTOR) and mitogen‐activated protein kinase pathways. This molecular dependency provides a strong mechanistic rationale for targeted ALK inhibition. Small‐molecule ALK inhibitors, including crizotinib, have demonstrated high overall response rates (67%–88%) and complete remission rates (~60%–80%) in relapsed or refractory ALK‐positive ALCL, often with rapid clinical responses. Next‐generation ALK inhibitors have shown activity in patients who progress on crizotinib, supporting the concept of sequential ALK‐targeted therapy to overcome acquired resistance. Resistance mechanisms include secondary ALK kinase domain mutations, such as L1196M and G1202R, as well as activation of compensatory signalling pathways, including PI3K/AKT/mTOR, underscoring the importance of molecular reassessment at relapse and the potential role of rational combination strategies. This review critically summarizes the molecular basis of ALK‐driven lymphomagenesis, evaluates the clinical evidence supporting ALK‐targeted therapy and discusses mechanisms of resistance. In addition, it explores emerging strategies for integrating ALK inhibitors into precision‐based management of T‐cell lymphomas, including combination approaches with chemotherapy, immunotherapy or antibody–drug conjugates. Collectively, these developments highlight a paradigm shift towards biology‐driven, personalized therapy in ALK‐positive ALCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large-Cell, AnaplasticProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesAntineoplastic AgentsHumansAnaplastic Lymphoma KinaseDrug Resistance, NeoplasmSignal TransductionMolecular Targeted Therapy

Stichwörter der Autor:innen

ALK inhibitorsALK‐positive anaplastic large cell lymphomaT‐cell lymphomasprecision medicinerelapsed/refractory T‐cell lymphomastargeted therapytyrosine kinase inhibitors

Substanzen

Anaplastic Lymphoma KinaseALK protein, humanProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesAntineoplastic Agents

Autor:innen und Institutionen

  • Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
  • Emergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine.
  • Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
  • AIL Sezione di Cosenza, Cosenza, Italy.

ORCID-Profile: Marco Fiorillo, Francesco Mendicino, Massimo Gentile

Zitieren

APA

Caserta, S., Martino, E. A., Skafi, M., Alvaro, M. E., Bruzzese, A., Amodio, N., Fiorillo, M., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Vigna, E., Morabito, F., & Gentile, M. (2026). Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration. British Journal of Haematology. https://doi.org/10.1111/bjh.70458

Vancouver

Caserta S, Martino EA, Skafi M, Alvaro ME, Bruzzese A, Amodio N, et al. Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration. British Journal of Haematology. 2026. doi:10.1111/bjh.70458

BibTeX
@article{Caserta2026,
  author = {Caserta, Santino and Martino, Enrica Antonia and Skafi, Mamdouh and Alvaro, Maria Eugenia and Bruzzese, Antonella and Amodio, Nicola and Fiorillo, Marco and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Vigna, Ernesto and Morabito, Fortunato and Gentile, Massimo},
  title = {Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70458}
}
Kostenlos starten →